BSE - Delayed Quote INR

Zenlabs Ethica Limited (ZENLABS.BO)

31.90
-0.69
(-2.12%)
At close: 3:46:10 PM GMT+5:30
Loading Chart for ZENLABS.BO
  • Previous Close 32.59
  • Open 33.00
  • Bid 31.89 x --
  • Ask --
  • Day's Range 31.18 - 33.00
  • 52 Week Range 27.33 - 44.29
  • Volume 5,397
  • Avg. Volume 8,924
  • Market Cap (intraday) 207.67M
  • Beta (5Y Monthly) -0.76
  • PE Ratio (TTM) 62.55
  • EPS (TTM) 0.51
  • Earnings Date Aug 5, 2025 - Aug 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jul 29, 2022
  • 1y Target Est --

Zenlabs Ethica Limited engages in the marketing and distribution of pharmaceutical products in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is also involved in the private label manufacturing of various pharmaceutical products, such as tablets, capsules, injections, syrups, and ointments; and therapeutics, such as anti-infective, anti-obesity, anti-bacterial, anti-hypertensives, anti-fungal, pain killers, and nutritional supplements. It serves customers through a network of distributors and stockists in Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, the Philippines, Singapore, Brunei, Timor-Leste, Bangladesh, and internationally. The company was formerly known as Neelkanth Technologies Limited and changed its name to Zenlabs Ethica Limited in January 2016. Zenlabs Ethica Limited was incorporated in 1993 and is based in Chandigarh, India.

www.zenlabsethica.com

65

Full Time Employees

March 31

Fiscal Year Ends

Recent News: ZENLABS.BO

View More

Performance Overview: ZENLABS.BO

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

ZENLABS.BO
18.77%
S&P BSE SENSEX (^BSESN)
4.08%

1-Year Return

ZENLABS.BO
20.25%
S&P BSE SENSEX (^BSESN)
11.25%

3-Year Return

ZENLABS.BO
20.25%
S&P BSE SENSEX (^BSESN)
54.05%

5-Year Return

ZENLABS.BO
20.25%
S&P BSE SENSEX (^BSESN)
161.32%

Compare To: ZENLABS.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZENLABS.BO

View More

Valuation Measures

Annual
As of 5/13/2025
  • Market Cap

    212.16M

  • Enterprise Value

    309.19M

  • Trailing P/E

    63.90

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.40

  • Price/Book (mrq)

    2.07

  • Enterprise Value/Revenue

    0.58

  • Enterprise Value/EBITDA

    11.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.62%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    537.64M

  • Net Income Avi to Common (ttm)

    3.31M

  • Diluted EPS (ttm)

    0.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    14.18M

  • Total Debt/Equity (mrq)

    110.52%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: ZENLABS.BO

View More

Company Insights: ZENLABS.BO

Research Reports: ZENLABS.BO

View More

People Also Watch